- Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge [published correction appears in Int J Stroke. 2020 Jan 28;:1747493020905964]. Int J Stroke. 2021;16(2):217–221. doi:10.1177/1747493019897870.
- Tanaka Y, Shah NS, Passman R, Greenland P, Lloyd-Jones DM, Khan SS. Trends in cardiovascular mortality related to atrial fibrillation in the United States, 2011 to 2018. JAHA. 2021;10(15):e020163. doi:10.1161/JAHA.120.020163.
- Lee E, Choi EK, Han KD, et al. Mortality and causes of death in patients with atrial fibrillation: a nationwide population-based study. PLoS One. 2018;13(12):e0209687. doi:10.1371/journal.pone.0209687.
- Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ Res. 2017;120(9):1501–1517. doi:10.1161/CIRCRESAHA.117.309732.
- Dai H, Zhang Q, Much AA, et al. Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990–2017: results from the Global Burden of Disease Study 2017. Eur Heart J Qual Care Clin Outcomes. 2021;7(6):574–582. doi:10.1093/ehjqcco/qcaa061.
- Alshehri AM. Stroke in atrial fibrillation: review of risk stratification and preventive therapy. J Family Community Med. 2019;26(2):92–97. doi:10.4103/jfcm.JFCM_99_18.
- National Guideline Centre (UK). Tools to Predict Stroke in People with Atrial Fibrillation: Atrial Fibrillation: Diagnosis and Management: Evidence Reviews C and D. London: National Institute for Health and Care Excellence (NICE); 2021.
- Chen JY, Zhang AD, Lu HY, Guo J, Wang FF, Li ZC. CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis. J Geriatr Cardiol. 2013;10(3):258–266. doi:10.3969/j.issn.1671-5411.2013.03.004.
- Parsons C, Patel SI, Cha S, et al. CHA2DS2-VASc score: a predictor of thromboembolic events and mortality in patients with an implantable monitoring device without atrial fibrillation. Mayo Clin Proc. 2017;92(3):360–369. doi:10.1016/j.mayocp.2016.10.008.
- Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867. doi:10.7326/0003-4819-146-12-200706190-00007.
- Waksman R, Pendyala LK. Overview of the Food and Drug Administration circulatory system devices panel meetings on WATCHMAN left atrial appendage closure therapy. Am J Cardiol. 2015;115(3):378–384. doi:10.1016/j.amjcard.2014.11.011.
- Osmancik P, Herman D, Neuzil P, PRAGUE-17 Trial Investigators, et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. J Am Coll Cardiol. 2020;75(25):3122–3135. doi:10.1016/j.jacc.2020.04.067.
- Sandhu O, Aftab Z, Anthony AT, Rahmat S, Khan S. Comparison between oral anticoagulation and left atrial appendage occlusion in the prevention of stroke with regard to non-valvular atrial fibrillation. Cureus. 2020;12(9):e10437. doi:10.7759/cureus.10437.
- Reddy VY, Sievert H, Halperin J, PROTECT AF Steering Committee and Investigators, et al. Percutaneous left atrial appendage closure vs. warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312(19):1988–1998. doi:10.1001/jama.2014.15192.
- Majule DN, Jing C, Rutahoile WM, Shonyela FS. The efficacy and safety of the WATCHMAN device in LAA occlusion in patients with non-valvular atrial fibrillation contraindicated to oral anticoagulation: a focused review. Ann Thorac Cardiovasc Surg. 2018;24(6):271–278. doi:10.5761/atcs.ra.18-00014.
- Kubo S, Mizutani Y, Meemook K, Nakajima Y, Hussaini A, Kar S. Incidence, characteristics, and clinical course of device-related thrombus after Watchman left atrial appendage occlusion device implantation in atrial fibrillation patients. JACC Clin Electrophysiol. 2017;3(12):1380–1386. doi:10.1016/j.jacep.2017.05.006.
- Dukkipati SR, Kar S, Holmes DR, et al. Device-related thrombus after left atrial appendage closure: incidence, predictors, and outcomes. Circulation. 2018;138(9):874–885. doi:10.1161/CIRCULATIONAHA.118.035090.
- Magdi M, Renjithal SLM, Mubasher M, et al. The WATCHMAN device and post-implantation anticoagulation management. A review of key studies and the risk of device-related thrombosis. Am J Cardiovasc Dis. 2021;11(6):714–722.
- Meier B, Blaauw Y, Khattab AA, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. EuroIntervention. 2015;10(9):1109–1125. doi:10.4244/EIJY14M08_18.
Association between rates of ischemic stroke and all-cause mortality with the Watchman device compared to warfarin and direct oral anticoagulants in patients with atrial fibrillation
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.